Jonathan Rothbard
Directeur Général chez Katexco Pharmaceuticals Corp.
Fortune : 2 434 $ au 30/06/2024
Profil
Jonathan B.
Rothbard is the founder of Amylin Pharmaceuticals, Inc. (founded in 1989), ImmuLogic Pharmaceutical Corp.
(founded in 1989), Cellgate, Inc. (founded in 1998), and Katexco Pharmaceuticals Corp.
(founded in 2018).
At ImmuLogic Pharmaceutical Corp., he held the title of Chief Scientific Officer-Palo Alto from 1989 to 1995.
At Cellgate, Inc., he held the title of Chief Scientific Officer from 1998 to 2004.
Currently, Dr. Rothbard is the Director, Chief Executive & Scientific Officer at CannBioRex Pharmaceuticals Corp.
He was previously the Chief Scientific Officer at KBL Merger Corp.
IV and the Head-Molecular Immunology Laboratory at Imperial Cancer Research Fund Trading Ltd.
Dr. Rothbard obtained a doctorate degree from The Trustees of Columbia University in The City of New York in 1977 and an undergraduate degree from Hamilton College (New York) in 1973.
Dr. Rothbard is also the founder of 180 Life Sciences Corp...Dr. Rothbard is also the founder of 180 Life Sciences Corp...
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
180 LIFE SCIENCES CORP.
0,16% | 29/04/2024 | 1 475 ( 0,16% ) | 2 434 $ | 30/06/2024 |
Postes actifs de Jonathan Rothbard
| Sociétés | Poste | Début |
|---|---|---|
Katexco Pharmaceuticals Corp.
 Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada. | Directeur Général | 01/11/2018 |
CannBioRex Pharmaceuticals Corp.
 CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Directeur Général | - |
Anciens postes connus de Jonathan Rothbard
| Sociétés | Poste | Fin |
|---|---|---|
| 180 LIFE SCIENCES CORP. | Fondateur | 07/05/2024 |
Cellgate, Inc.
 Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | Fondateur | 01/01/2004 |
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Fondateur | 01/01/1995 |
| Imperial Cancer Research Fund Trading Ltd. | Corporate Officer/Principal | - |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Fondateur | - |
Formation de Jonathan Rothbard
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| Hamilton College (New York) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| 180 LIFE SCIENCES CORP. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
ImmuLogic Pharmaceutical Corp.
ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Health Technology |
Cellgate, Inc.
Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | Health Technology |
KBL Merger Corp. IV
 KBL Merger Corp. IV Financial ConglomeratesFinance KBL Merger Corp. IV is a blank check company, which focuses on acquiring an operating company in the healthcare and related wellness industry. The company was founded on September 7, 2016 and is headquartered in New York, NY. | Finance |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Health Technology |
Katexco Pharmaceuticals Corp.
Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada. | Health Technology |
